Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone transdermal - ANI Pharmaceuticals/Antares

Next Previous
Drug Profile

Testosterone transdermal - ANI Pharmaceuticals/Antares

Alternative Names: Bio-T-Gel; LibiGel; Male testosterone gel - ANI Pharmaceuticals/Teva Pharmaceuticals USA; Testosterone ATD™ Gel; Testosterone topical gel - ANI Pharmaceuticals/Antares; Testosterone transdermal - Antares/BioSante

Latest Information Update: 26 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antares Pharma
  • Developer ANI Pharmaceuticals; Teva Pharmaceuticals USA
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cognition disorders; Female sexual dysfunction; Hypogonadism

Most Recent Events

  • 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics
  • 28 Nov 2017 No recent reports on development identified - Registered for Hypogonadism in USA (Transdermal)
  • 13 May 2015 Testosterone transdermal is no longer licensed to Teva in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top